In the latest trading session, 2.8 million Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) shares changed hands as the company’s beta touched 0.82. With the company’s most recent per share price at $17.42 changing hands around $0.36 or 2.08% at last look, the market valuation stands at $19.76B. TEVA’s current price is a discount, trading about -30.88% off its 52-week high of $22.80. The share price had its 52-week low at $11.83, which suggests the last value was 32.09% up since then. When we look at Teva- Pharmaceutical Industries Ltd. ADR’s average trading volume, we note the 10-day average is 17.38 million shares, with the 3-month average coming to 11.29 million.
Analysts gave the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TEVA as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Teva- Pharmaceutical Industries Ltd. ADR’s EPS for the current quarter is expected to be 0.51.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Instantly TEVA is in green as seen in intraday trades today. With action -6.07%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -20.98%, with the 5-day performance at -6.07% in the red. However, in the 30-day time frame, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) is -18.01% down. Looking at the short shares, we see there were 15.8 million shares sold at short interest cover period of 1.26 days.
The consensus price target for the stock as assigned by Wall Street analysts is 25.5, meaning bulls need an upside of 31.69% from its recent market value. According to analyst projections, TEVA’s forecast low is 22 with 28 as the target high. To hit the forecast high, the stock’s price needs a -60.73% plunge from its current level, while the stock would need to soar -26.29% for it to hit the projected low.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts
Data shows that the Teva- Pharmaceutical Industries Ltd. ADR share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 4.41% over the past 6 months, a 10.84% in annual growth rate that is considerably lower than the industry average of 27.40%. Year-over-year growth is forecast to reach 3.14% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 4B. 5 analysts are of the opinion that Teva- Pharmaceutical Industries Ltd. ADR’s revenue for the current quarter will be 4.31B. The company’s revenue for the corresponding quarters a year ago was 3.82B and 4.16B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 4.68%. The estimates for the next quarter sales put growth at 3.49%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 26.63%. The 2025 estimates are for Teva- Pharmaceutical Industries Ltd. ADR earnings to increase by 4.44%, but the outlook for the next 5-year period is at 5.66% per year.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR is expected to release its next quarterly earnings report in March. During the past 5 years, the average dividend yield was 2.95 per year.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.00% of Teva- Pharmaceutical Industries Ltd. ADR shares while 58.23% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 58.23%. There are 58.23% institutions holding the Teva- Pharmaceutical Industries Ltd. ADR stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 3.8279% of the shares, roughly 42.99 million TEVA shares worth $698.55 million.
FMR LLC holds the second largest percentage of outstanding shares, with 3.7381% or 41.98 million shares worth $682.15 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Contrafund Inc and iShares Core MSCI EAFE ETF. With 14.11 shares estimated at $245.07 million under it, the former controlled 1.25% of total outstanding shares. On the other hand, iShares Core MSCI EAFE ETF held about 0.63% of the shares, roughly 7.16 shares worth around $124.33 million.
